237 related articles for article (PubMed ID: 36548906)
1. Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?
Zuzda K; Grycuk W; Małyszko J; Małyszko J
Expert Opin Ther Targets; 2022 Nov; 26(11):995-1009. PubMed ID: 36548906
[TBL] [Abstract][Full Text] [Related]
2. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
[TBL] [Abstract][Full Text] [Related]
3. Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease.
Farrah TE; Anand A; Gallacher PJ; Kimmitt R; Carter E; Dear JW; Mills NL; Webb DJ; Dhaun N
Hypertension; 2019 Aug; 74(2):323-330. PubMed ID: 31177906
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.
Athyros VG; Tziomalos K; Karagiannis A
Expert Rev Cardiovasc Ther; 2015; 13(9):1059-66. PubMed ID: 26206619
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
Katsiki N; Mikhailidis DP; Banach M
Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332
[No Abstract] [Full Text] [Related]
6. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.
Zheng-Lin B; Ortiz A
Drugs; 2018 Feb; 78(2):215-229. PubMed ID: 29299849
[TBL] [Abstract][Full Text] [Related]
7. Is lipid management effective for all stages of CKD?
Ku E; Campese V
Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
[TBL] [Abstract][Full Text] [Related]
8. Lipid management in patients with chronic kidney disease.
Ferro CJ; Mark PB; Kanbay M; Sarafidis P; Heine GH; Rossignol P; Massy ZA; Mallamaci F; Valdivielso JM; Malyszko J; Verhaar MC; Ekart R; Vanholder R; London G; Ortiz A; Zoccali C
Nat Rev Nephrol; 2018 Dec; 14(12):727-749. PubMed ID: 30361677
[TBL] [Abstract][Full Text] [Related]
9. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
Shaik A; Kosiborod M; de Lemos JA; Gao Q; Mues KE; Alam S; Bhatt DL; Cannon CP; Ballantyne CM; Rosenson RS;
Clin Cardiol; 2022 Dec; 45(12):1303-1310. PubMed ID: 36124341
[TBL] [Abstract][Full Text] [Related]
10. Dyslipidemia in patients with chronic kidney disease.
Hager MR; Narla AD; Tannock LR
Rev Endocr Metab Disord; 2017 Mar; 18(1):29-40. PubMed ID: 28000009
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin/kexin type 9 in kidney disease.
Schmit D; Fliser D; Speer T
Nephrol Dial Transplant; 2019 Aug; 34(8):1266-1271. PubMed ID: 31190079
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease.
Quiroga B; Muñoz Ramos P; Álvarez Chiva V
Nefrologia (Engl Ed); 2020; 40(5):499-505. PubMed ID: 32682569
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
14. Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy.
Kratky V; Valerianova A; Hruskova Z; Tesar V; Malik J
Curr Atheroscler Rep; 2024 Apr; 26(4):103-109. PubMed ID: 38289577
[TBL] [Abstract][Full Text] [Related]
15. Dyslipidemia in Patients with Kidney Disease.
Thobani A; Jacobson TA
Cardiol Clin; 2021 Aug; 39(3):353-363. PubMed ID: 34247749
[TBL] [Abstract][Full Text] [Related]
16. [Statins: what is their place in the treatment of chronic kidney insufficiency?].
Ponte B; Bourquin V; Stoermann-Chopard C
Rev Med Suisse; 2009 Feb; 5(192):463-4, 466-8. PubMed ID: 19317313
[TBL] [Abstract][Full Text] [Related]
17. A Clinical Guide to Combination Lipid-Lowering Therapy.
Russell C; Sheth S; Jacoby D
Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
[TBL] [Abstract][Full Text] [Related]
18. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
[TBL] [Abstract][Full Text] [Related]
19. Discovery Approaches for Novel Dyslipidemia Drugs.
Maqbool F; Safavi M; Bahadar H; Rahimifard M; Niaz K; Abdollahi M
Curr Drug Discov Technol; 2015; 12(2):90-116. PubMed ID: 26135857
[TBL] [Abstract][Full Text] [Related]
20. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
